Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Maria Soler Nunez appointed as Chief Quality Officer
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Subscribe To Our Newsletter & Stay Updated
